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PreviewsCD37, which contains two additional
tyrosines Y274 and Y280, somehow inhibits
CD37 phosphorylation and the cytotoxic
effects of SMIP-016. This led to the
finding that SMIP-016 also activates the
PI3K-AKT proliferative signaling pathway.
Treatment of cells with the PI3K inhibitor
LY294002 or deleting the C-terminal tail
of CD37 increases SMIP-016-induced
killing. In summary, SMIP-016 simulta-
neously activates both SHP-1 mediated
death signaling and PI3K-AKT mediated
survival signaling.
The study of Lapalombella et al. (2012)
not only provides deeper insight into
the molecular mechanisms of SMIP-016
action but may also help guide current
and future clinical trials using TRU-016.
For example, the current study reveals
an opposing role for PI3K and an absolute
requirement for SHP-1 expression for
efficacy of SMIP-016. Consistent with
its tumor suppressor role, expression of598 Cancer Cell 21, May 15, 2012 ª2012 ElsSHP-1 is diminished or absent in many
leukemias and lymphomas (Wu et al.,
2003). Thus, it can be expected that
cancers with low or no SHP-1 expression
may not respond to TRU-016 treatment.
The results from current TRU-016 clinical
trials on CLL are expected in the first
half of 2013, and in interpreting the
outcome, it may be useful to stratify
subjects based on the SHP-1 expression
level and the PI3K pathway activity in their
tumors.
REFERENCES
Barrena, S., Almeida, J., Yunta, M., Lopez, A.,
Fernandez-Mosteirin, N., Giralt, M., Romero, M.,
Perdiguer, L., Delgado, M., Orfao, A., and Lazo,
P.A. (2005). Leukemia 19, 1376–1383.
Hainsworth, J.D., Litchy, S., Barton, J.H., Houston,
G.A., Hermann, R.C., Bradof, J.E., and Greco, F.A.
(2003). J. Clin. Oncol. 21, 1746–1751.
Knobeloch, K.P., Wright, M.D., Ochsenbein, A.F.,
Liesenfeld, O., Lohler, J., Zinkernagel, R.M., Horak,evier Inc.I., and Orinska, Z. (2000). Mol. Cell. Biol. 20, 5363–
5369.
Lapalombella, R., Yeh, Y., Wang, L., Ramanunni,
A., Rafig, S., Jha, S., Staubli, J., Lucas, D.M.,
Mani, R., Herman, S.E.M., et al. (2012). Cancer
Cell 21, this issue, 694–708.
Robak, T., Robak, P., and Smolewski, P. (2009).
Curr. Opin. Investig. Drugs 10, 1383–1390.
Sheng, K.C., van Spriel, A.B., Gartlan, K.H., Sofi,
M., Apostolopoulos, V., Ashman, L., and Wright,
M.D. (2009). Eur. J. Immunol. 39, 50–55.
Tarrant, J.M., Robb, L., van Spriel, A.B., and
Wright, M.D. (2003). Trends Immunol. 24, 610–617.
van Spriel, A.B., Sofi, M., Gartlan, K.H., van der
Schaaf, A., Verschueren, I., Torensma, R., Ray-
makers, R.A., Loveland, B.E., Netea, M.G., Adema,
G.J., et al. (2009). PLoS Pathog. 5, e1000338.
Wu, C., Sun, M., Liu, L., and Zhou, G.W. (2003).
Gene 306, 1–12.
Zhao, X., Lapalombella, R., Joshi, T., Cheney, C.,
Gowda, A., Hayden-Ledbetter, M.S., Baum, P.R.,
Lin, T.S., Jarjoura, D., Lehman, A., et al. (2007).
Blood 110, 2569–2577.Opening a New GATAway
for Treating KRAS-Driven Lung TumorsMariano Barbacid1,*
1Molecular Oncology Programme, Centro Nacional de Investigaciones Oncolo´gicas (CNIO), E-28029 Madrid, Spain
*Correspondence: mbarbacid@cnio.es
DOI 10.1016/j.ccr.2012.04.032
In a recent issue of Cell, Kumar and colleagues uncovered a synthetic lethal interaction between oncogenic
KRAS and the transcription factor GATA2 in non-small cell lung carcinoma. Pharmacological inhibition
of GATA2-mediated pathways with bortezomib and fasudil results in dramatic tumor inhibition. These obser-
vations unveil new armamentaria to fight this deadly disease.Non-small cell lung carcinoma (NSCLC)
hasoneof thehighest incidenceand lowest
survival rates, a combination that makes
this tumor type one of the deadliest human
cancers. At least a quarter of NSCLC
expressamutantKRASallele that encodes
a constitutively active small G protein
known tosignal throughaseriesof kinases.
While these kinases are in principle ame-
nable to pharmacological intervention,
a selective treatment for KRAS mutant
NSCLC is not yet available in the clinic.
During the last decade, there have been
significant efforts directed to reproducethe natural history of NSCLC in genetically
engineered mouse (GEM) models (Heyer
et al., 2010). Recently, these models have
been utilized to evaluate potential thera-
peutic targets. Some of the validated
targets include well-known downstream
elements of KRAS signaling such as
components of the mitogenic RAF/MEK/
ERK cascade and the PI3K/AKT survival
pathway, most of which are druggable
kinases (Gupta et al., 2007; Engelman
et al., 2008;Blasco et al., 2011) (Figure 1A).
However, these studies cannot be directly
extrapolated to the clinic because targetablation occurred during tumor initiation
rather than during tumor progression.
Moreover, these Kras oncogene-driven
GEM models retained the full component
of tumor suppressors and, hence, do not
develop metastatic tumors.
Other studies have attempted to vali-
date pathways less directly linked to
KRAS signaling. In one study, elimination
of CDK4, but not the other interphase
CDKs, elicited a rapid senescence
response that resulted in partial tumor
regression, an observation validated with
clinically available CDK4 inhibitors (Puyol
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Figure 1. Preclinical Studies to Validate Therapeutic Targets in KRAS-Driven NSCLC
(A) Schematic diagram of putative therapeutic targets validated by genetic approaches in GEMmodels of NSCLCs driven by residentKras oncogenes. (Left) GEM
models driven by conditional mutant Kras alleles develop adenomas and non-metastatic adenocarcinomas (in blue). (Right) GEMmodels that also carry mutated
or null Tp53 or have Tp53 knockdown develop more aggressive adenocarcinomas (in red) that frequently metastasize to distant organs.
(B) RNAi screens aimed at identifying human genes capable of inducing synthetic lethality in combination with KRAS oncogenes.
(C) Pharmacologic approaches using selective targeted inhibitors in the above Kras-driven GEM models. Original references for these GEM models have been
omitted due to space limitations.
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Previewset al., 2010) (Figure 1A). Other studies
have examined the therapeutic conse-
quences of inhibiting the NF-kB pathway
in GEM models carrying Tp53 null alleles
or expressing reduced levels of p53
(Meylan et al., 2009; Xia et al., 2012).
When challenged with an IkB super-
repressor or when IKKb expression was
knocked down, tumors regressed,
although they were not completely elimi-
nated (Figure 1). These observations sug-
gest that blocking NF-kB-driven survival
pathways might serve as a therapeutic
strategy to thwart KRAS-driven tumor
progression.
Other investigators have expanded
the repertoire of KRAS targets by search-
ing for synthetic lethal genes using RNA
interference (RNAi) libraries. Screens of
human NSCLC cell lines carrying either
wild-type or mutant KRAS have identified
targets linked to the cell cycle such as
PLK1, a kinase involved in mitotic pro-gression and to the NF-kB pathway such
as TKB1, a non-canonical IkB kinase
(Barbie et al., 2009; Luo et al., 2009)
(Figure 1B). In vivo validation of these
synthetic lethal genes will establish their
therapeutic value in KRAS-driven lung
tumors.
In a recent issue of Cell, the Downward
laboratory (Kumar et al., 2012) went all
the way from identifying GATA2 as a
novel synthetic lethal gene to validating
it using Kras-driven GEM models and,
finally, to demonstrating its therapeutic
potential by using surrogate drugs already
approved for clinical use (Figure 1). Kumar
et al. (2012) screened human NSCLC cell
lines carrying either wild-type or mutant
KRAS with an RNAi library against 7,000
human genes. Using cell viability as the
biological read-out, they identified the
transcription factor GATA2 essential for
the proliferation of cell lines carrying
oncogenic KRAS. GATA2 knockdownCancer Celalso reduced the viability of cell lines
carrying mutated loci functionally related
to KRAS such as NRAS, NF1, EML4-
ALK, and EGFR. Interestingly, GATA2 is
an unlikely actor in lung cancer because
its function has, so far, only been linked
to the hematopoietic system.
Gene set enrichment analysis revealed
that reduction of GATA2-mediated tran-
scription in lung tumor cells affected
several pathways, suggesting that a
pleiotropic effect is required for the
observed synthetic lethality. Knockdown
of GATA2 affected proteosomal activity
in lung tumor cells, an observation remi-
niscent of that obtained in previous
screens (Barbie et al., 2009; Luo et al.,
2009). This effect appears to be indepen-
dent of the presence of oncogenic KRAS
and is not sufficient to induce loss of cell
viability. GATA2 depletion also led to
transcriptional repression of IL-1 and
NF-kB signaling pathways. In this case,l 21, May 15, 2012 ª2012 Elsevier Inc. 599
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Previewssome of the observed effects, mainly
expression of TRAF6, were specific for
KRAS mutant cells. Yet, direct inhibition
of either IL-1 signaling by its antagonist
IL-1ra or of NF-kB signaling by TRAF6
knockdown did not result in loss of cell
viability, suggesting that inhibition of
either pathway alone is not sufficient to
phenocopy loss of GATA2 expression.
Finally, Kumar et al. (2012) identified that
some genes involved in RHO-related
signaling pathways were occupied by
GATA2 in KRAS mutant but not wild-
type tumor cells. Not surprisingly,
GATA2 knockdown in KRAS mutant cells
resulted in a striking reduction of active
GTP-bound RHO proteins, including the
downstream ROCK kinase. Restoration
of RHO activity by expression of con-
stitutively active RHO proteins or by
a ROCK-ER fusion kinase did not rescue
cell viability in the absence of GATA2,
again suggesting that blocking RHO
signaling is not sufficient to mimic loss
of GATA2 activity. Intriguingly, KRAS
oncogene knockdown, while affecting
cell viability of KRAS mutant cells to a
similar extent as GATA2 knockdown,
had no effect on the proteasome path-
way, NF-kB activity, or RHO signaling.
These observations suggest that GATA2
is not a downstream component of the
KRAS oncogenic signaling pathway.
Conditional ablation of Gata2 alleles
in a Kras-driven GEM model of NSCLC
prevented tumor initiation. More impor-
tantly, systemic elimination of Gata2 in
mice already presenting Kras-driven lung
tumors resulted in substantial tumor
regression without major side effects
suggesting that blocking GATA2 activity600 Cancer Cell 21, May 15, 2012 ª2012 Elscould have therapeutic value and might
be well tolerated in patients. Whether
inhibition of GATA2 results in defects in
the immune system (a phenotype that
might not be obvious in the protected
environment of an animal facility) remains
to be determined.
Finally, Kumar et al. (2012) combined
available inhibitors selective for two of
the pathways regulated by GATA2 to treat
mice with Kras-driven NSCLCs. The
chosen inhibitors bortezomib (a protea-
some inhibitor) and fasudil (a RHO/
ROCK inhibitor) have already been
approved for use in human patients.
When combined, these inhibitors induced
almost complete regression of well-es-
tablished lung tumors in the Kras-driven
GEM model (Figure 1C). These observa-
tions are reminiscent of a previous report
in which similar tumors also regressed
upon treatment with a combination of
MEK and PI3K inhibitors (Engelman
et al., 2008). However, MEK inhibitors
have not been approved by the FDA due
to undesired toxicities, and PI3K inhibitors
have thus far shown rather limited anti-
tumor activity.
Are we on the verge of a major break-
through in the treatment ofKRAS-induced
NSCLC? Possibly; however, we should
consider the data of Kumar et al. (2012)
as an exciting but early step in the long
process of drug discovery. The GEM
model used in this study retains wild-
type Tp53, suggesting that the tumors
successfully treated with bortezomib
and fasudil might not be as aggressive
as those in most NSCLC patients. More-
over, the in vivo data is still preliminary
and other potential roadblocks such asevier Inc.drug resistance have not been examined.
In spite of these caveats, the results of
Kumar et al. (2012) represent a very
important advance in the long-standing
fight to conquer lung cancer. Undoubt-
edly, they have opened an important
‘‘GATAway’’ toward this challenging goal.
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